Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short-term Investments (2023 - 2025)

Historic Short-term Investments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $17.3 million.

  • BioLineRx's Short-term Investments fell 1494.32% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year decrease of 1494.32%. This contributed to the annual value of $9.1 million for FY2024, which is 7644.23% down from last year.
  • Per BioLineRx's latest filing, its Short-term Investments stood at $17.3 million for Q3 2025, which was down 1494.32% from $21.0 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Short-term Investments ranged from a high of $38.7 million in Q4 2023 and a low of $9.1 million during Q4 2024
  • Its 3-year average for Short-term Investments is $22.9 million, with a median of $21.0 million in 2025.
  • Examining YoY changes over the last 5 years, BioLineRx's Short-term Investments showed a top increase of 3401.88% in 2024 and a maximum decrease of 7644.23% in 2024.
  • Quarter analysis of 3 years shows BioLineRx's Short-term Investments stood at $38.7 million in 2023, then tumbled by 76.44% to $9.1 million in 2024, then surged by 89.55% to $17.3 million in 2025.
  • Its Short-term Investments stands at $17.3 million for Q3 2025, versus $21.0 million for Q2 2025 and $17.3 million for Q1 2025.